Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:50 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001297184-26-000047
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Reconciliation to net cash provided by operating activities: | ||
| Loss on disposal of assets | 13 | 32 |
| (Gain) loss on interest rate swaps and foreign currency transactions, net | (1,295) | 1,736 |
| Depreciation of property, plant, and equipment | 16,120 | 15,716 |
| Amortization of intangible assets | 12,539 | 12,509 |
| Operating lease right-of-use asset amortization | 4,293 | 3,221 |
| Amortization of discounts, premiums, and debt issuance costs | 1,636 | 1,604 |
| Share-based compensation expense | 16,364 | 14,775 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Amphastar Pharmaceuticals's D&A?
- Amphastar Pharmaceuticals (AMPH) reported D&A of $8.04M in Q2 2026.
- How has Amphastar Pharmaceuticals's D&A changed year-over-year?
- Amphastar Pharmaceuticals's D&A decreased by 3.7% year-over-year, from $8.35M to $8.04M.
- What is the long-term trend for Amphastar Pharmaceuticals's D&A?
- Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's D&A has grown at a 9.3% compound annual growth rate (CAGR), from $22.2M to $31.65M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Amphastar Pharmaceuticals's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude